STOCK TITAN

Apellis Pharmaceuticals Inc - APLS STOCK NEWS

Welcome to our dedicated news page for Apellis Pharmaceuticals (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apellis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apellis Pharmaceuticals's position in the market.

Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) reported $397 million in full-year 2023 revenues, with strong sales for SYFOVRE® and EMPAVELI®. The company highlighted the successful launch of SYFOVRE and positive reception for EMPAVELI. They are focused on expanding market reach, advancing their pipeline, and delivering for patients. Financially, Apellis had $351 million in cash as of December 31, 2023, with total revenue of $146.4 million in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
earnings
-
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) will participate in upcoming investor conferences in March 2024, including TD Cowen 44th Annual Healthcare Conference and Raymond James & Associates’ 45th Annual Institutional Investors Conference. The company will host fireside chats and panel discussions, with live webcasts available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
conferences
-
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) schedules a conference call to discuss its fourth quarter and full year 2023 financial results on February 27, 2024. Investors can access the call via phone or live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences earnings
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) granted equity awards to 4 new employees outside of the 2017 Stock Incentive Plan. Each employee received 6,265 restricted stock units (RSUs) that will vest annually over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a negative opinion from the CHMP of the European Medicines Agency on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration. The company plans to seek immediate re-examination of its application. The MAA is based on results from the Phase 3 OAKS and DERBY studies at 24 months, which showed promising treatment effects over time and a well-demonstrated safety profile. However, the negative opinion is disappointing for the millions of Europeans living with GA, a progressive and irreversible form of vision loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) reports approximately $138 million in preliminary U.S. net product revenues for the fourth quarter of 2023, with strong sales of SYFOVRE® and EMPAVELI®. SYFOVRE® garnered approximately $114 million, and EMPAVELI® contributed approximately $24 million. The company also highlighted high patient compliance rates and increased use of the EMPAVELI Injector. These results were presented at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
none
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) approved the grant of equity awards to 2 new employees as equity inducement awards outside of the company's 2017 Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Each employee received 1,960 restricted stock units (RSUs) that will vest annually over a 4-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences
-
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast and a replay will be available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
conferences
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company plans to appeal the outcome and seek re-examination of the opinion after the CHMP adopts a negative opinion at its next meeting in January 2024. The MAA is based on results from the Phase 3 OAKS and DERBY studies at 24 months, which showed promising treatment effects and a well-demonstrated safety profile. However, the negative trend vote has led to disappointment among company executives and the retina community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.02%
Tags
none
Apellis Pharmaceuticals Inc

Nasdaq:APLS

APLS Rankings

APLS Stock Data

7.70B
80.99M
13.23%
95.8%
8.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Waltham

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.